These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 11432621)

  • 1. The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study.
    Kornblith AB; Herndon JE; Zuckerman E; Godley PA; Savarese D; Vogelzang NJ;
    Ann Oncol; 2001 May; 12(5):633-41. PubMed ID: 11432621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.
    Savarese DM; Halabi S; Hars V; Akerley WL; Taplin ME; Godley PA; Hussain A; Small EJ; Vogelzang NJ
    J Clin Oncol; 2001 May; 19(9):2509-16. PubMed ID: 11331330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.
    Savarese D; Taplin ME; Halabi S; Hars V; Kreis W; Vogelzang N
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):39-44. PubMed ID: 10604268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
    Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
    BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer.
    Sitka Copur M; Ledakis P; Lynch J; Hauke R; Tarantolo S; Bolton M; Norvell M; Muhvic J; Hake L; Wendt J
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):16-21. PubMed ID: 11685724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
    Petrylak DP; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
    N Engl J Med; 2004 Oct; 351(15):1513-20. PubMed ID: 15470214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
    Oh WK; Kantoff PW
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):49-54. PubMed ID: 10604270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer.
    Wada Y; Kikuchi K; Takahashi W; Honda J; Nakanishi J; Matsumoto K; Kuwahara T; Kai N; Kikukawa H; Ueda S
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):53-61. PubMed ID: 17375305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel and docetaxel in prostate cancer.
    Obasaju C; Hudes GR
    Hematol Oncol Clin North Am; 2001 Jun; 15(3):525-45. PubMed ID: 11525295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
    Kreis W; Budman DR; Fetten J; Gonzales AL; Barile B; Vinciguerra V
    Ann Oncol; 1999 Jan; 10(1):33-8. PubMed ID: 10076719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.
    Smith DC; Esper P; Strawderman M; Redman B; Pienta KJ
    J Clin Oncol; 1999 Jun; 17(6):1664-71. PubMed ID: 10561202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
    Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF
    J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
    Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
    Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer.
    Kreis W; Budman D
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):34-8. PubMed ID: 10604267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
    Dawson NA; Halabi S; Ou SS; Biggs DD; Kessinger A; Vogelzang N; Clamon GH; Nanus DM; Kelly WK; Small EJ;
    Clin Genitourin Cancer; 2008 Sep; 6(2):110-6. PubMed ID: 18824434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer.
    Eymard JC; Priou F; Zannetti A; Ravaud A; Lepillé D; Kerbrat P; Gomez P; Paule B; Genet D; Hérait P; Ecstein-Fraïssé E; Joly F
    Ann Oncol; 2007 Jun; 18(6):1064-70. PubMed ID: 17434899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
    Kattan JG; Farhat FS; Chahine GY; Nasr FL; Moukadem WT; Younes FC; Yazbeck NJ; Ghosn MG;
    Invest New Drugs; 2008 Feb; 26(1):75-9. PubMed ID: 17846704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy for androgen-independent prostate cancer.
    Petrylak DP
    Semin Urol Oncol; 2002 Aug; 20(3 Suppl 1):31-5. PubMed ID: 12198636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
    Hussain M; Smith DC; El-Rayes BF; Du W; Vaishampayan U; Fontana J; Sakr W; Wood D
    Urology; 2003 Apr; 61(4):774-80. PubMed ID: 12670564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.
    Petrylak DP; Macarthur R; O'Connor J; Shelton G; Weitzman A; Judge T; England-Owen C; Zuech N; Pfaff C; Newhouse J; Bagiella E; Hetjan D; Sawczuk I; Benson M; Olsson C
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):28-33. PubMed ID: 10604266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.